9887.HK

Shares of Nanjing Leads Biolab Co. Ltd. (9887.HK) rose 91.7% to close at HK$67.10 on their first trading day on Friday, after the company sold  36.86 million shares for HK$35 each, representing the top of their range. The public offering for local Hong Kong investors was oversubscribed by approximately 3,494 times, while the international placement was oversubscribed by almost 40 times.

The listing raised net proceeds of HK$1.18 billion ($150 million), 65% of which will be used for clinical development of the company’s products and for regulatory purposes. Another 15% will go to expand the company’s existing pipeline and to improve its technology platform, while 10% will go for improvement of its production capacity. The rest will be used for general working capital.

By Lau Chi Hang

To subscribe to Bamboo Works weekly free newsletter, clickhere

Recent Articles

WeRide is enjoying a payoff from expanding its global taxi flee

Robotaxi rollout drives faster earnings pace at WeRide

The driverless technology company is enjoying a payoff from expanding its global taxi fleet, with quarterly revenues surging and losses continuing to shrink Key Takeaways: Third-quarter revenue more than doubled,…
Illustration of Luckin and Costa coffee being tasted

Luckin Coffee eyes global leap as China’s Double 11 loses its luster

Luckin could be preparing a bid for Costa Coffee. What's driving this potential deal, and what are its chances for success? And this year's Double 11 festival looks like a dud, with most big e-commerce companies failing to publish any big numbers. What does the future hold for this fast-fading shopping fest?